TrialAdvances in therapy2022

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.

Annabelle A Okada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.